BRIEF-Concert Pharmaceuticals says announces CTP-543 positive top-line Phase 1 results

* Concert pharmaceuticals - CTP-543 well-tolerated across

all dose groups in study & there were no serious adverse events

in subjects who received CTP-543

Read more